Punit Dhillon, Skye Bioscience CEO
Obesity drugmaker lands first biopharma uplisting onto Nasdaq since last summer
For the first time since last summer, a biotech has uplisted from an over-the-counter stock exchange to the Nasdaq. Such a move has become a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
